Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model

Joshua A. Wood, Evan Colletti, Laura E. Mead, David Ingram, Christopher D. Porada, Esmail D. Zanjani, Mervin C. Yoder, Graça Almeida-Porada

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Although the vasculogenic potential of circulating and cord blood (CB)-derived endothelial colony-forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Here we used a fetal sheep model of in utero transplantation to investigate and compare the intrinsic ability of human CB-derived ECFC to migrate to the liver and to the intestine, and to define ECFC's intrinsic ability to integrate and contribute to the cytoarchitecture of these same organs. ECFCs were transplanted by an intraperitoneal or intrahepatic route (IH) into fetal sheep at concentrations ranging from 1.1-2.6 × 106 cells/fetus. Recipients were evaluated at 85 days posttransplant for donor (human) cells using flow cytometry and confocal microscopy. We found that, regardless of the route of injection, and despite the IH delivery of ECFC, the overall liver engraftment was low, but a significant percentage of cells were located in the perivascular regions and retained the expression of hallmark endothelial makers. By contrast, ECFC migrated preferentially to the intestinal crypt region and contributed significantly to the myofibroblast population. Furthermore, ECFC expressing CD133 and CD117 lodged in areas where endogenous cells expressed those same phenotypes. Conclusion: ECFC inherently constitute a potential source of cells for the treatment of intestinal diseases, but strategies to increase the numbers of ECFC persisting within the hepatic parenchyma are needed in order to enhance ECFC therapeutic potential for this organ.

Original languageEnglish (US)
Pages (from-to)1086-1096
Number of pages11
JournalHepatology
Volume56
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Fetal Blood
Sheep
Liver
Intestinal Diseases
Myofibroblasts
Confocal Microscopy
Population
Intestines
Flow Cytometry
Fetus
Transplantation

ASJC Scopus subject areas

  • Hepatology

Cite this

Wood, J. A., Colletti, E., Mead, L. E., Ingram, D., Porada, C. D., Zanjani, E. D., ... Almeida-Porada, G. (2012). Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model. Hepatology, 56(3), 1086-1096. https://doi.org/10.1002/hep.25753

Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model. / Wood, Joshua A.; Colletti, Evan; Mead, Laura E.; Ingram, David; Porada, Christopher D.; Zanjani, Esmail D.; Yoder, Mervin C.; Almeida-Porada, Graça.

In: Hepatology, Vol. 56, No. 3, 01.09.2012, p. 1086-1096.

Research output: Contribution to journalArticle

Wood, Joshua A. ; Colletti, Evan ; Mead, Laura E. ; Ingram, David ; Porada, Christopher D. ; Zanjani, Esmail D. ; Yoder, Mervin C. ; Almeida-Porada, Graça. / Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model. In: Hepatology. 2012 ; Vol. 56, No. 3. pp. 1086-1096.
@article{4d987f84fb9c462d8da2bd3f1b6ccc95,
title = "Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model",
abstract = "Although the vasculogenic potential of circulating and cord blood (CB)-derived endothelial colony-forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Here we used a fetal sheep model of in utero transplantation to investigate and compare the intrinsic ability of human CB-derived ECFC to migrate to the liver and to the intestine, and to define ECFC's intrinsic ability to integrate and contribute to the cytoarchitecture of these same organs. ECFCs were transplanted by an intraperitoneal or intrahepatic route (IH) into fetal sheep at concentrations ranging from 1.1-2.6 × 106 cells/fetus. Recipients were evaluated at 85 days posttransplant for donor (human) cells using flow cytometry and confocal microscopy. We found that, regardless of the route of injection, and despite the IH delivery of ECFC, the overall liver engraftment was low, but a significant percentage of cells were located in the perivascular regions and retained the expression of hallmark endothelial makers. By contrast, ECFC migrated preferentially to the intestinal crypt region and contributed significantly to the myofibroblast population. Furthermore, ECFC expressing CD133 and CD117 lodged in areas where endogenous cells expressed those same phenotypes. Conclusion: ECFC inherently constitute a potential source of cells for the treatment of intestinal diseases, but strategies to increase the numbers of ECFC persisting within the hepatic parenchyma are needed in order to enhance ECFC therapeutic potential for this organ.",
author = "Wood, {Joshua A.} and Evan Colletti and Mead, {Laura E.} and David Ingram and Porada, {Christopher D.} and Zanjani, {Esmail D.} and Yoder, {Mervin C.} and Gra{\cc}a Almeida-Porada",
year = "2012",
month = "9",
day = "1",
doi = "10.1002/hep.25753",
language = "English (US)",
volume = "56",
pages = "1086--1096",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model

AU - Wood, Joshua A.

AU - Colletti, Evan

AU - Mead, Laura E.

AU - Ingram, David

AU - Porada, Christopher D.

AU - Zanjani, Esmail D.

AU - Yoder, Mervin C.

AU - Almeida-Porada, Graça

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Although the vasculogenic potential of circulating and cord blood (CB)-derived endothelial colony-forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Here we used a fetal sheep model of in utero transplantation to investigate and compare the intrinsic ability of human CB-derived ECFC to migrate to the liver and to the intestine, and to define ECFC's intrinsic ability to integrate and contribute to the cytoarchitecture of these same organs. ECFCs were transplanted by an intraperitoneal or intrahepatic route (IH) into fetal sheep at concentrations ranging from 1.1-2.6 × 106 cells/fetus. Recipients were evaluated at 85 days posttransplant for donor (human) cells using flow cytometry and confocal microscopy. We found that, regardless of the route of injection, and despite the IH delivery of ECFC, the overall liver engraftment was low, but a significant percentage of cells were located in the perivascular regions and retained the expression of hallmark endothelial makers. By contrast, ECFC migrated preferentially to the intestinal crypt region and contributed significantly to the myofibroblast population. Furthermore, ECFC expressing CD133 and CD117 lodged in areas where endogenous cells expressed those same phenotypes. Conclusion: ECFC inherently constitute a potential source of cells for the treatment of intestinal diseases, but strategies to increase the numbers of ECFC persisting within the hepatic parenchyma are needed in order to enhance ECFC therapeutic potential for this organ.

AB - Although the vasculogenic potential of circulating and cord blood (CB)-derived endothelial colony-forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Here we used a fetal sheep model of in utero transplantation to investigate and compare the intrinsic ability of human CB-derived ECFC to migrate to the liver and to the intestine, and to define ECFC's intrinsic ability to integrate and contribute to the cytoarchitecture of these same organs. ECFCs were transplanted by an intraperitoneal or intrahepatic route (IH) into fetal sheep at concentrations ranging from 1.1-2.6 × 106 cells/fetus. Recipients were evaluated at 85 days posttransplant for donor (human) cells using flow cytometry and confocal microscopy. We found that, regardless of the route of injection, and despite the IH delivery of ECFC, the overall liver engraftment was low, but a significant percentage of cells were located in the perivascular regions and retained the expression of hallmark endothelial makers. By contrast, ECFC migrated preferentially to the intestinal crypt region and contributed significantly to the myofibroblast population. Furthermore, ECFC expressing CD133 and CD117 lodged in areas where endogenous cells expressed those same phenotypes. Conclusion: ECFC inherently constitute a potential source of cells for the treatment of intestinal diseases, but strategies to increase the numbers of ECFC persisting within the hepatic parenchyma are needed in order to enhance ECFC therapeutic potential for this organ.

UR - http://www.scopus.com/inward/record.url?scp=84865571024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865571024&partnerID=8YFLogxK

U2 - 10.1002/hep.25753

DO - 10.1002/hep.25753

M3 - Article

C2 - 22488442

AN - SCOPUS:84865571024

VL - 56

SP - 1086

EP - 1096

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -